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Purpose: To study the effect of different polymers on the solubility and dissolution rate of cefuroxime 
axetil (CFU) prepared by emulsion solvent diffusion (ESD) technique.   
Methods: The ESD technique employed involved three test solvents: first, substance dissolution 
medium-good solvent (acetone); second, partial dissolution medium for the substance-bridging liquid 
(dichloromethane), and third, immiscible with the substance-poor solvent (distilled water). The pure CFU  
and the prepared agglomerates were characterized in terms of production yield,  drug content, solubility, 
in vitro release profile,  flowability, density, wettability, as well as by thin layer chromatography (TLC), 
differential scanning calorimetry (DSC), x-ray diffraction (XRD), Fourier transforms infra red 
spectroscopy (FTIR) and stability test.  
Results: DSC showed a decrease in the melting enthalpy indicating disorder in the crystalline content. 
XRD also indicated changes in crystallinity, FTIR revealed that there were no chemical changes in the 
recrystallized agglomerates while dissolution data demonstrated a marked increase in the dissolution 
rate (>55 % in 45 min) compared with the pure drug (35% in 45 min). The improvement in the 
dissolution rate of CFU from optimized crystal formulation was attributed to the wetting effect of the 
polymers, change in drug crystallinity, altered surface morphology and micronization. The recrystallized 
agglomerates also exhibited higher wettability and flowability.      
Conclusion: The optimised recrystallized agglomerates exhibited good solubility, wettability, dissolution 
rate and other physicochemical properties compared to the unmodified CFU. 
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INTRODUCTION 
 
Aqueous solubility and dissolution are two of 
the crucial factors influencing drug absorption 
from the gastrointestinal tract (GIT). 
However, many newly discovered 
compounds exhibit low oral bioavailability. 
The oral route is convenient for 
administration of drugs compared to other 
routes; therefore, in developing novel oral 
drug delivery systems, different strategies are 
employed to increase the solubility and 
dissolution of liphophilic drugs, e.g., particle 
size reduction, solid dispersion, complexation 
with cyclodextrins, etc. 
 
Several methods of reducing particle size 
have been suggested. They include physical 
methods such as milling and grinding
1
, but it 
is difficult to obtain uniform fine particles and 
control the particle size of the drug. 
Microcrystallization of hydrophobic drugs is a 
technique to overcome these problems
2
. The 
process is usually used to obtain small 
particles by the disruption of large crystals 
Dissolution rate and bioavailability 
improvement by micronization of sparingly 
water-soluble drugs entail using jar mills and 
fluid energy mills
3
. However, the 
micronization process is extremely inefficient 
due to the involvement of high energy 
nanoparticles and physical and/or chemical 
instability caused by disruptions in the crystal 
lattice
4- 6
. Spray-drying of a drug solution is 
another way to produce micron-sized 
spherical particles. Spray-dried drugs, which 
are amorphous, show a smaller and more 
homogeneous particle size than mechanically 
micronized drugs
7,8
. However, as a fine 
particle fraction, even spray-dried amorphous 




The spherical crystallization technique has 
already been successfully applied to improve 
the micromeritic properties of acebutolol 
hydrochloride
10
. In the most common case, 
this technique is reputed to improve the 
wettability and dissolution rate of different 
drugs
11-14
. Some drugs have also been 
recrystallized by the spherical agglomeration 
technique using polymeric materials to modify 
their release
15,16
. There are two main 
methods of spherical crystallization: spherical 
agglomeration (SA) and emulsion solvent 
diffusion (ESD). 
 
Cefuroxime is the first commercially available 
second generation cephalosporin which is 
active against a wide range of Gram-positive 
and Gram-negative organisms and is 
resistant to most β-lactamases. It is a semi-
synthetic cephalosporin obtained from the 7-
cephalosporanic acid nucleus of 
cephalosporin
17
. Cefuroxime axetil (CFU) is 
the acetoxyethyl ester of the cephalosporin, 
cefuroxime (a prodrug of cefuroxime). It is a 
Biopharmaceutics Classification System 
(BCS) class II drug and has only 55% 
absolute oral bioavailability due to poor 
aqueous solubility. Since it is slightly soluble 
in water and can form a thicker gel on contact 
with aqueous medium, therefore, it shows 
poor dissolution and consequently, low 




In this work, an attempt has been made to 
enhance the solubility, dissolution rate and 
other physicochemical properties of CFU by 
an emulsion solvent diffusion (EDS) method. 
The method employs three solvents: (i) 
substance dissolution medium (good 
solvent), (ii) partially dissolution medium for 
the substance (bridging liquid), and (iii) one 
that is immiscible with the substance (poor 
solvent). ESD is the particle engineering 
technique by which crystallization and 
agglomeration can be carried out 
simultaneously in one step to transform 
crystals directly into a compacted spherical 
form
19
. This particle design technique has 
emerged as one of the areas of research 
interest in pharmaceutical manufacturing and 
has gained considerable attention due to the 
fact that crystal habit (form, surface, size and 
particle size distribution) can be modified 
during the crystallization process. 
Consequently, certain micrometric properties 
(bulk density, flow property, compactability) 
and physicochemical characteristics 
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Cefuroxime axetil was received as a gift from 
Okasa Pharma (Satara, India). Methocel 
(HPMC, E-5) and hydroxypropyl cellulose 
were supplied by Colorcon, (Goa, India). 
Glyceryl monostearte was procured from 
Alembic (Vadodara, India) while Eudagit 
RLPO was obtained from Degussa India Pvt. 
Ltd Research Centre (Mumbai, India). 
Acetone and dichloromethane were 
purchased from S.D. Fine Chemicals 
(Mumbai, India). 
 
Preparation of cefuroxime axetil agglome-
rates  
 
All spherical agglomerates were obtained by 
the emulsion solvent diffusion (ESD) method 
at room temperature using distilled water (as 
external phase and poor solvent). The 
internal phase contained a good solvent 
(acetone) and a bridging liquid 
(dichloromethane) with cefuroxime axetil 
(CFU, 1g), 0.25g of polymer (either Eudragit 
RLPO, hydroxypropyl cellulose (HPC) or 
hydroxypropyl methylcellulose (HPMC)) 
mixed separately with glyceryl monostearate 
(0.25g). The agglomerates were coded CFU-
RLPO, CFU-HPC and CFU-HPMC 
accordingly.   
 
In the ESD method, the drug, and polymer 
and glyceryl monostearate were co-dissolved 
in an organic solvent mixture of 
dichloromethane (5ml) and acetone (5ml). 
The drug-polymer solution was slowly added 
to the external phase (150ml) containing 
0.25% PVA under agitation at 1000 rpm. The 
system was stirred continuously for about 12 
h. As the good solvent diffused into the poor 
solvent, droplets gradually solidified and 
formed spherical agglomerates. The system 
was filtered through Whatman filter paper no. 
42 under the vacuum to separate the 
spherical agglomerates. The resultant 
product was washed with distilled water and 
dried in a hot air oven at 40 
0
C for 12 h.  
 
Yield and drug content 
 
The dried agglomerates were weighed and 
the production yield calculated. Each 
agglomerate (300mg) was powdered, from 
which a sample equivalent to 100 mg CFU 
was weighed and extracted with three 
portions of 50mL 0.07N HCl. Each portion 
was filtered through a G-4 sintered glass filter 
and volume was adjusted to 100 mL with the 
same extraction medium. After sufficient 
dilution with 0.07N HCl, samples were 
analyzed spectrophotometrically (Pharma 
Spec 1700, Shimadzu Corporation, Kyoto, 
Japan) at 281 nm and CFU content was 
calculated. The test was performed in 
triplicate.   
 
Saturation solubility studies   
 
Saturation solubility studies were carried out 
using deionized water as a solvent. 
Excessive quantity (sample 150 mg) of 
sample (pure drug or agglomerate) was taken 
in six screw capped test tubes with fixed 
volume (10 ml) of deionized water. The 
resultant suspension was shaken at room 
temperature in an incubator shaker at 100 
rpm for 24 h after which samples were 
withdrawn and filtered through 0.2µ filters 
(Ultipor®N66, Pall Life sciences, Mumbai, 
India). The filtrate was suitably diluted with 
0.07N HCl and analyzed at 281 nm by 
UV/VIS spectrophotometry. Triplicate 
measurements were made. 
 
In vitro drug release study  
 
The release rate of cefuroxime axetil and the 
agglomerates (sample equivalent to 100 mg 
drug) were performed in 900 ml of 0.07 N HCl 
using USP Apparatus II (Disso 2000, Lab 
India Pvt. Ltd, Mumbai, India) set at 37±0.2
0
C 
(n=6) and rotated at 55 rpm. Samples (5 ml) 
were withdrawn at regular intervals and 
replaced with the same volume of fresh 
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dissolution medium to maintain sink 
conditions. The samples were suitably diluted 
with the dissolution medium and drug content 
assayed spectrophotometrically at 281 nm 
(Pharma Spec 1700, Shimadzu Corporation, 
Kyoto, Japan).  
 
Measurement of flowability and density   
 
The loose bulk density (LBD) and tapped bulk 
densities (TBD) were determined by using a 
density measuring apparatus (Serwell, 
Bangalore, India). An amount of the sample 
(5g) was placed in a measuring cylinder and 
the volume (bulk volume) was measured after 
applying three taps. Tapped density was 
measured as per USP using the procedure 
described by Lafaver
20
. A quantity (20g) of 
the material was passed through a 1 mm 
aperture sieve and transferred to a 100mL 
graduated cylinder. The surface was carefully 
leveled out compacting the material. The 
unsettled apparent volume was noted. .The 
cylinder was tapped at a rate of 300 
drops/min over a fixed drop distance of 
14±2mm. After the first 500 drops, the 
volume of the material in the cylinder was 
measured. Further tapping (750 and then 
1250 drops successively) was applied was 
applied until the difference between two 
volumes following successive tapping was 
less than 2.0%. This final volume was taken 
as the tapped volume. Bulk and tapped 
densities, Carr’s index (%) and Hausner’s 
ratio were calculated as in Eqs. 1 - 4. Angle 
of repose of the materials were assessed by 
the fixed funnel method and computed as in 
Eq. 5.  The results presented are the means 
of three determinations each.  
 
Bulk density (σb) = Weight / Bulk volume …    (1) 
Tapped density (σt) = Weight / Tapped volume ...   (2) 
Carr’s Index = [(σt – σb) / σt] x 100   .....  (3) 
Hausner ratio = (σt / (σb)   ………… ….. (4) 
Angle of repose (θ) = Tan
-1
(h/r)  ……….. (5) 
 
Wettability study  
 
Powder bed hydrophilicity test was carried 
out to assess the wettability of the 
agglomerates  by placing the sample (2 g) in 
sintered glass tube to form a bed in the glass 
tube on which methylene blue crystals (≈100 
mg) were placed. The tube was brought into 
contact with the surface of water and the time 
taken for water to rise by capillary movement 
to dissolve methylene blue crystals was 
noted. The shortest time corresponds to the 
most wettable sample. The test was 
performed in triplicate. 
 
Differential scanning calorimetric (DSC) 
studies  
 
Differential scanning calorimetric (DSC) 
analysis of the samples was carried out with 
a DSC analyzer (model TA–60, Shimadzu 
Corporation, Kyoto, Japan). A sample (3-7 
mg) was sealed in an aluminum pan with a 
perforated lid and heated under nitrogen 
atmosphere at a heating rate of 10 °C/min 
over the temperature range of 20 – 210 
0
C. 
The thermograms were obtained and 
recorded. 
 
X-ray powder diffraction (XRPD) studies   
 
The XRPD patterns of the samples were 
monitored with an x-ray diffractometer 
(Philips PW 1729, Analytical XRD, Holland) 
using Ni filtered CuK(α) radiation (intensity 
ratio(α1/ α2): 0.500), voltage of 40 KV, current 
of 30 mA and receiving slit of 0.2 inches. The 
samples were analyzed over 2θ range of 
5.010-39.990
o
 with scanning step size of 
0.020
o
 (2θ) and scan step time of one 
second. To minimize the effect of particle size 
on preferred orientation, all the samples were 
first passed through sieve  no. 120 (125µm) 
and collected on sieve  no.  240 (62.5µm).  
 
Fourier transforms infra red spectroscopy 
(FTIR) studies    
 
The FT-IR spectra of the agglomerates and 
the pure drug (embedded in potassium 
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bromide pellet) were recorded on Shimadzu 
FTIR – 8400 spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan). Background 
spectrum was obtained under identical 
conditions. Each spectrum was derived from 
single average scans collected in the region 
400 – 4000 cm
-1
 at a spectral resolution of 2 
cm
-2
 and rationed against background 
interferogram. The spectra were analyzed by 




The data was analyzed using GraphPad 
InState Demo and Microsoft Excel 2003. 
One-way analysis of variance (ANOVA) and 
Dunnett Multiple Comparisons Test were 
used test the statistical significance of the 
data. P < 0.0001 was considered extremely 
significant. Variation among column means 
was significantly greater than expected by 
chance. If the value of q is greater than 2.880 
then the P value is less than 0.05. 
 
RESULTS   
 
The physicochemical and other properties of 
the CFU and its agglomerates are listed in 
Table 1. The yield of the recrystallized 
agglomerates was between 88 and 92% 
while drug content was in the range 93-96%. 
The aqueous solubility of CFU in the 
agglomerates was between 1.33 and 1.59 
mg/ml compared to 0.3 mg/ml for the pure 
drug. Thus, there was a significant 
improvement in solubility (P<0.01).  
 
Flowability was assessed in terms of angle of 
repose, Carr’s index and Hausnar ratio. The 
agglomerates had significantly lower angle of 
repose (P < 0.01) with the value in the range 
of 20.0 – 22.6
0
 as against 39.7
0
 for CFU, due 
to the irregular shape of the crystals, which 
facilitated the uniform flow of crystals from 
the funnel. Carr’s index results reveal that 
flowability of CFU was also significantly 
poorer (P < 0.01) than those of the 
agglomerates with the latter having lower 
Carr index than pure CFU. Hausner ratio data 
similarly indicate that the agglomerates 
exhibited better flowability than the pure drug.  
The wettability test results in Table 1 indicate 
that the agglomerates  were significantly (P < 
0.01) more wettable with a water-rising time 
of 6.9 – 8.0 h compared to 13.0 h for the pure 
drug The order of wettability was CFU-RLPO 
> CFU-HPMC > CFU-HPC > CFU.  
 
The in vitro drug release data, shown in 
Figure 1, revealed that drug release rates of 
the CFU agglomerates were largely similar 
but greater than that of the pure CFU.  
Powder X-ray diffraction patterns, displayed 
in Figure 2, indicate  that pure  CFU  did  not 
 
 
Table 1: Physicochemical characteristics of CFU and recrystallized agglomerates (n= 3)  
 
Product  code CFU CFU-RLPO CFU-HPMC CFU-HPC 
Production yield (%)  ------ 92.2±0.2 88.6±0.2 90.1±0.3 
Solubility (mg/ml) 0.30±0.27 1.51±0.35 1.33±0.15 1.59±0.35 
Content (%) 97.0±0.6 95.0±0.5 94.0±0.6 95.0±0.3 
Solubility (mg/ml)  0.16±0.03 0.15±0.02 0.31±0.03 0.34±0.02 
Water-rising time (h)  13.0 ± 0.6 6.9 ± 0.6 7.0 ± 0.3 8.0 ± 0.2 
Angle of Repose (
0
) 39.7 ± 0.3 20.0 ± 0.3 22.6 ± 0.2 21.4 ± 0.3 
Carr’s Index 29.9 ± 0.5 15.8 ± 1.0 11.8 ± 0.4 15.6 ± 0.4 
Hausner Ratio 1.29 ± 0.63 1.12 ± 0.54 1.07 ± 0.29 1.10 ± 0.38 
   
Yadav & Yadav 















Figure 1:  In vitro release profile of CFU and CFU agglomerates ( ; 




Figure 2: X-ray powder diffraction patterns of CFU 
and CFU agglomerates 
 
show any peak suggesting that it is 
amorphous. The XRPD pattern of the 
agglomerates differed in the characteristic 
peak for cefuroxime axetil from that of the 
pure drug, thus confirming the existence of 
new compounds. There was a difference in d-
values (i.e., the distance between the 
successive two atomic planes of the crystals) 
between the XRPD spectrum of CFU and 
those of the agglomerates. For the DSC 
results (see Figure 3), the untreated drug 
showed a small endothermic diffuse peak at 
212 
0
C corresponding to its fusion 
temperature, and thus, melting point. The 
corresponding endothermic peaks for CFU-
RLPO, CFU-HPC and CFU-HPMC occurred 





Figure 3: DSC thermograms of CFU and CFU 
agglomerates 
 
The FTIR results are illustrated in Figure 4 
and they reveal that the peak at 1685.34 cm
-
1
, corresponding to an amide group usually at 
1695.34 cm
-1




occurred at a 
higher wave
 
number. For the agglomerates, 
there is a shift to a lower frequency with 
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change in intensity, suggesting a change in 
the environment of the C=O group associated 
with the amide moiety. The presence of 





aromatic ether in the drug and agglomerates 
and this suggests that there is no change in 
the environment of this moiety. The 





 are attributed to stretching 
vibration of the amide carbonyl in the ester 









The method used for the preparation of the 
CFU agglomerates was emulsion solvent 
diffusion (ESD) technique. In this method, 
when bridging liquid plus good solvent 
solution of the drug, along with different 
polymers, were poured into the poor solvent 
(dispersion medium) under agitation, quasi-
emulsion droplets of bridging liquid or good 
solvent form the emulsion droplet in the 
dispersing medium and induces the 
crystallization of the drug followed by 
agglomeration. The continuous phase is a 
liquid in which the drug solution is immiscible, 
and crystallization occurs inside the droplets 
because of counter diffusion of solvents 
through the droplets. The average diameter 
of the agglomerate crystals increased with 
increasing content of dichloromethane (DCM) 
in the system due to the enhanced 
agglomeration of powdery crystals. When the 
amount of acetone in the system was 
increased, while keeping the amount of DCM 
constant, the diffusion rate of acetone and 
DCM from the droplets was enhanced with 
increase in the content of acetone in the 
system. The increase in diffusion rate of DCM 
from the droplets shortened the 
agglomeration process of the crystals 
produced in the droplets while decrease in 
the DCM content of droplets reduced the 
agglomeration force of the crystal due to the 
increase in the unwetted part of the crystals 
with DCM in the agglomerates resulting in the 
formation of flocks with pendular bridges of 
water. Thus, the particle diameter and 
recovery of agglomerates decreased with 
increase in the acetone content of the 
system.  
 
Physicochemical properties  
 
The presence of the polymer, Eudragit, in 
CFU-RLPO enhanced the ability of the 
compound to form micelles, due to the 
presence of quaternary groups in the 
polymer, and thus increased the solubility of 
CFU. On the other hand, the presence of 
HPMC and HPC on the CFU particle surface 
would increase particle-particle interaction, 
thus causing faster squeezing out of DCM to 
the surface, and resulting in increased 
particle size and strength of agglomerates. 
Furthermore, improvement in the solubility of 
the agglomerates may also be due to 
changes in the crystal forms as well as 
changes in crystal habit, structure and 
surface modification. In some instances, 
solvents incorporated into the crystals form 
solvets or clathrate that changes surface 
properties, reactivity of drug particles and the 
internal energy of the molecules, which play 
important roles in solubility improvement. The 
addition of HPMC and HPC, which are water-
soluble polymers as stated earlier, increases 
the solubility of CFU in water by adsorbing on 
to the drug particle surface during 
agglomeration. 
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The reason for the excellent flowability of the 
recrystallized agglomerates may be a 
reduction in interparticle friction as a result of 
probably a more spherical particle shape as 
well as larger crystal size. The rationale for 
the superior wettability of agglomerates is 
that the polymers adhere to the CFU crystals 
while their faster dissolution or release 
properties can be linked to their better 
wettability.  
 
The agglomerates show slightly lower melting 
points than the pure drug but this may not be 
related to a change in the internal structure of 
the drug molecule. However, the change in 
the characteristic peaks and d-values can be 
linked to crystal habit modification while 
changes in the intensity of the peaks indicate 
a different arrangement of the molecules and 
hence suggest the development of new 
polymorphic forms.  
 
In the FTIR study, the slight shift of the 
absorption band for the carbonyl group of the 
amide to a lower frequency can be attributed 
to the breakdown of the intermolecular 
hydrogen bond associated with the crystalline 
drug molecule and formation of hydrogen 
bond between the monomeric drug and the 
polymers. Overall, no changes occurred in 
the chemistry of CFU and there was no great 





The ESD technique used in this study 
produced agglomerates that exhibited 
significantly faster dissolution rates than the 
unmodified CFU crystals. The improved 
solubility and dissolution are attributable to 
the modification of CFU within the 
agglomerates due to specific interactions 
between the drug and the polymers, as well 
as increased wettability and a reduction in 
particle size. When this is taken together with 
improvements in other physicochemical 
properties, such as flowability and wettability, 
the ESD technique can be considered a 
suitable method for formulating CFU 
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